RedHill Biopharma (RDHL) Cost of Revenue (2014 - 2023)

RedHill Biopharma (RDHL) has reported Cost of Revenue for 8 consecutive years, with $806000.0 the latest figure, recorded in Q2 2023.

• On a quarterly basis, Cost of Revenue fell 91.04% year-over-year to $806000.0 in Q2 2023; TTM through Jun 2023 was $20.5 million, a 53.33% decrease from a year earlier, with the FY2025 full-year figure at $2.0 million, down 38.08% from the prior year.
• Cost of Revenue was $806000.0 for Q2 2023 at RedHill Biopharma, down from $1.6 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $19.3 million in Q4 2021 and troughed at $417000.0 in Q1 2019.
• A 5-year average of $6.9 million and a median of $8.8 million in 2022 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue surged 3238.35% in 2020 and tumbled 91.04% in 2023, its largest moves.
• Over 5 years, Cost of Revenue stood at $788000.0 in 2019, then jumped by 1251.78% to $10.7 million in 2020, then jumped by 81.51% to $19.3 million in 2021, then sank by 55.53% to $8.6 million in 2022, then plunged by 90.63% to $806000.0 in 2023.
• The last three Cost of Revenue figures came in at $806000.0 (Q2 2023), $1.6 million (Q1 2023), and $8.6 million (Q4 2022), per Business Quant data.